Cargando…
Adverse reactions following routine anticholinergic eye drops in a paediatric population: an observational cohort study
OBJECTIVES: To investigate the presence, nature and relationship to age, sex, ethnicity and body mass index (BMI) of adverse reactions following routine cycloplegic eye drops in children. DESIGN: Prospective observational cohort study. SETTING: Ophthalmology outpatient clinic Dutch metropolitan hosp...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4691733/ https://www.ncbi.nlm.nih.gov/pubmed/26700273 http://dx.doi.org/10.1136/bmjopen-2015-008798 |
_version_ | 1782407184474177536 |
---|---|
author | van Minderhout, Helena M Joosse, Maurits V Grootendorst, Diana C Schalij-Delfos, Nicoline E |
author_facet | van Minderhout, Helena M Joosse, Maurits V Grootendorst, Diana C Schalij-Delfos, Nicoline E |
author_sort | van Minderhout, Helena M |
collection | PubMed |
description | OBJECTIVES: To investigate the presence, nature and relationship to age, sex, ethnicity and body mass index (BMI) of adverse reactions following routine cycloplegic eye drops in children. DESIGN: Prospective observational cohort study. SETTING: Ophthalmology outpatient clinic Dutch metropolitan hospital; February, March and April 2009. PARTICIPANTS: Children aged 3–14-year-old children receiving two drops of cyclopentolate 1% (C+C) or one drop of cyclopentolate 1% and one drop of tropicamide 1% (C+T). Patients were categorised by age (3–6, 7–10 and 11–14 years), sex, ethnicity and body mass index (BMI) (low, normal or high). OUTCOME MEASURES: Rate and nature of adverse reactions reported at 45 min following treatment. Crude and adjusted ORs for reporting an adverse reaction using stepwise regression analysis with BMI, age, ethnicity and sex. RESULTS: 912 of 915 eligible patients participated (99.7%). Adverse reactions were reported for C+C in 10.3% and in C+T in 4.8% (42/408 and 24/504, p=0.002), respectively. Central effects were present in 95% in C+C and in 92% in C+T. Compared to C+T, an increased risk was present in C+C (crude OR 2.3 (1.4 to 3.9), p=0.002). Forward adjustment showed BMI to be an influencing factor in treatment (OR 3.1 (1.7 to 5.6), p<0.001). In a multivariate model, a dose of cyclopentolate remained associated with adverse reactions. Analysis per BMI and regime and age category and regime, indicated associations with low BMI (OR C+C 21.4 (6.7 to 67.96), p<0.001, respectively, C+T 5.2 (2.1 to 12.8), p<0.001) and young age (OR C+C 8.1 (2.7 to 24.8), p<0.001). CONCLUSIONS: Adverse reactions were common and almost exclusively involved the central nervous system. Both presence and severity were associated with repeated instillation of cyclopentolate 1%, low BMI and young age. In specific paediatric populations, a single dose of cyclopentolate must be considered. Vital function monitoring facilities are advisable. Adjustment of guidelines is recommended. |
format | Online Article Text |
id | pubmed-4691733 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-46917332015-12-30 Adverse reactions following routine anticholinergic eye drops in a paediatric population: an observational cohort study van Minderhout, Helena M Joosse, Maurits V Grootendorst, Diana C Schalij-Delfos, Nicoline E BMJ Open Ophthalmology OBJECTIVES: To investigate the presence, nature and relationship to age, sex, ethnicity and body mass index (BMI) of adverse reactions following routine cycloplegic eye drops in children. DESIGN: Prospective observational cohort study. SETTING: Ophthalmology outpatient clinic Dutch metropolitan hospital; February, March and April 2009. PARTICIPANTS: Children aged 3–14-year-old children receiving two drops of cyclopentolate 1% (C+C) or one drop of cyclopentolate 1% and one drop of tropicamide 1% (C+T). Patients were categorised by age (3–6, 7–10 and 11–14 years), sex, ethnicity and body mass index (BMI) (low, normal or high). OUTCOME MEASURES: Rate and nature of adverse reactions reported at 45 min following treatment. Crude and adjusted ORs for reporting an adverse reaction using stepwise regression analysis with BMI, age, ethnicity and sex. RESULTS: 912 of 915 eligible patients participated (99.7%). Adverse reactions were reported for C+C in 10.3% and in C+T in 4.8% (42/408 and 24/504, p=0.002), respectively. Central effects were present in 95% in C+C and in 92% in C+T. Compared to C+T, an increased risk was present in C+C (crude OR 2.3 (1.4 to 3.9), p=0.002). Forward adjustment showed BMI to be an influencing factor in treatment (OR 3.1 (1.7 to 5.6), p<0.001). In a multivariate model, a dose of cyclopentolate remained associated with adverse reactions. Analysis per BMI and regime and age category and regime, indicated associations with low BMI (OR C+C 21.4 (6.7 to 67.96), p<0.001, respectively, C+T 5.2 (2.1 to 12.8), p<0.001) and young age (OR C+C 8.1 (2.7 to 24.8), p<0.001). CONCLUSIONS: Adverse reactions were common and almost exclusively involved the central nervous system. Both presence and severity were associated with repeated instillation of cyclopentolate 1%, low BMI and young age. In specific paediatric populations, a single dose of cyclopentolate must be considered. Vital function monitoring facilities are advisable. Adjustment of guidelines is recommended. BMJ Publishing Group 2015-12-22 /pmc/articles/PMC4691733/ /pubmed/26700273 http://dx.doi.org/10.1136/bmjopen-2015-008798 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Ophthalmology van Minderhout, Helena M Joosse, Maurits V Grootendorst, Diana C Schalij-Delfos, Nicoline E Adverse reactions following routine anticholinergic eye drops in a paediatric population: an observational cohort study |
title | Adverse reactions following routine anticholinergic eye drops in a paediatric population: an observational cohort study |
title_full | Adverse reactions following routine anticholinergic eye drops in a paediatric population: an observational cohort study |
title_fullStr | Adverse reactions following routine anticholinergic eye drops in a paediatric population: an observational cohort study |
title_full_unstemmed | Adverse reactions following routine anticholinergic eye drops in a paediatric population: an observational cohort study |
title_short | Adverse reactions following routine anticholinergic eye drops in a paediatric population: an observational cohort study |
title_sort | adverse reactions following routine anticholinergic eye drops in a paediatric population: an observational cohort study |
topic | Ophthalmology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4691733/ https://www.ncbi.nlm.nih.gov/pubmed/26700273 http://dx.doi.org/10.1136/bmjopen-2015-008798 |
work_keys_str_mv | AT vanminderhouthelenam adversereactionsfollowingroutineanticholinergiceyedropsinapaediatricpopulationanobservationalcohortstudy AT joossemauritsv adversereactionsfollowingroutineanticholinergiceyedropsinapaediatricpopulationanobservationalcohortstudy AT grootendorstdianac adversereactionsfollowingroutineanticholinergiceyedropsinapaediatricpopulationanobservationalcohortstudy AT schalijdelfosnicolinee adversereactionsfollowingroutineanticholinergiceyedropsinapaediatricpopulationanobservationalcohortstudy |